These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 9805025

  • 1. The quandary of Creutzfeldt-Jakob disease.
    Larke B.
    CMAJ; 1998 Oct 06; 159(7):789-92. PubMed ID: 9805025
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Notifying patients exposed to blood products associated with Creutzfeldt-Jakob disease: integrating science, legal duties and ethical mandates.
    Caulfield T, Dossetor J, Boshkov L, Hannon J, Sawyer D, Robertson G.
    CMAJ; 1997 Nov 15; 157(10):1389-92. PubMed ID: 9371070
    [Abstract] [Full Text] [Related]

  • 5. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products.
    Turner ML, Ludlam CA.
    Br J Haematol; 2009 Jan 15; 144(1):14-23. PubMed ID: 18950452
    [Abstract] [Full Text] [Related]

  • 6. Creutzfeld-Jakob disease: the Grace General Hospital experience.
    Pauls F, Hayes J, Read J.
    Leadersh Health Serv; 1996 Jan 15; 5(6):42-3. PubMed ID: 10163983
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comment: limiting toxic information.
    Howe EG.
    J Clin Ethics; 2001 Jan 15; 12(2):143-9. PubMed ID: 11642066
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Blood supplies hit by vCJD fear.
    Strachan-Bennett S.
    Nurs Times; 2001 Jan 15; 100(1):6. PubMed ID: 14735624
    [No Abstract] [Full Text] [Related]

  • 11. Recipients of blood or blood products "at vCJD risk".
    Bird SM.
    BMJ; 2004 Jan 17; 328(7432):118-9. PubMed ID: 14726314
    [No Abstract] [Full Text] [Related]

  • 12. Prion diseases.
    Knight R.
    Vox Sang; 2004 Jul 17; 87 Suppl1():104-6. PubMed ID: 15200617
    [No Abstract] [Full Text] [Related]

  • 13. Creutzfeldt-Jakob disease and haemophilia: assessment of risk.
    Evatt B.
    Haemophilia; 2000 Jul 17; 6 Suppl 1():94-9. PubMed ID: 10982274
    [No Abstract] [Full Text] [Related]

  • 14. The success of precaution? Managing the risk of transfusion transmission of variant Creutzfeldt-Jakob disease.
    Wilson K, Ricketts MN.
    Transfusion; 2004 Oct 17; 44(10):1475-8. PubMed ID: 15383021
    [Abstract] [Full Text] [Related]

  • 15. Creutzfeldt-Jakob disease: the problem of recipient notification.
    DuVal G.
    J Law Med Ethics; 1997 Oct 17; 25(1):34-41, 3. PubMed ID: 11066473
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [The National Board of Health and Welfare on Creutzfeldt-Jakob disease: physicians are to be notified about suspected cases].
    Tüll P.
    Lakartidningen; 2000 Sep 13; 97(37):4045. PubMed ID: 11036368
    [No Abstract] [Full Text] [Related]

  • 19. Variant Creutzfeldt-Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty.
    Farrugia A, Ironside JW, Giangrande P.
    Vox Sang; 2005 Nov 13; 89(4):186-92. PubMed ID: 16262750
    [Abstract] [Full Text] [Related]

  • 20. Ask the ethicist: would you tell the patients?
    Culver CM.
    Med Ethics (Burlingt Mass); 2000 Nov 13; ():3. PubMed ID: 15719509
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.